The GLP-1 Gold Rush: Are Consumers Buying Weight Loss or Just Hype?

 

The bold claim Elon Musk made captures how dramatically GLP-1 drugs have moved beyond their original medical purpose. Have you ever set out to achieve a goal, only to realize that the most remarkable result was something you never planned for? Glucagon-like-peptide-1 (GLP-1) drugs, initially designed for blood sugar level regulation, were used in obesity treatment due to their significant weight loss effects. The popularity of GLP-1 medications continues to grow, fuelled by intense advertising and celebrity endorsements, leading to increasing demand even among those without medical requirements. About 1 in 8 American adults now take a GLP-1 drug while nearly 1 in 5 say they have tried one at some point (kffrainl, 2025). However, this trend raises economic concerns about whether consumers have enough information about the risks, side effects, and proper use of these drugs. This blog shows that the GLP-1 boom is a case of asymmetric information, where noisy signals and distorted incentives can lead to inefficient market outcomes. Photo source: (Alones Creative, 2025) Asymmetric information ⚖️ At first glance, the GLP-1 market looks like a simple success story: demand is booming, clinics are expanding, and the drugs are constantly discussed online. But beneath that excitement lies a more uncomfortable question-do consumers really know as much as the sellers do? Photo source: Shutterstock (zimmytws, 2025) In reality, they don’t. Pharmaceutical companies and aesthetic clinics are typically more aware of the risks, side effects, and limitations of GLP-1 drugs than the ordinary consumer. This kind of unequal information is what economists call asymmetric information. Yet these downsides are often invisible and persuasive compared to fast-acting weight loss effects that consumers see, especially on celebrities.   For example, Wegovy, one brand of GLP-1, clearly lists several serious side effect warnings, including pancreatitis, gallbladder problems, kidney damage risk, and thyroid tumor warnings in its official report (Wegovy, 2026). Although this information exists, it is rarely the first thing consumers see. In reality, many are more likely to encounter celebrity transformations, social media hype, or eye-catching advertising than detailed medical guidance. Reuters reported that Novo Nordisk spent nearly $500 million in advertising dollars on Wegovy and Ozempic in the United States alone in the first nine months of 2025 (Varghese and Wingrove, 2026). These campaigns drown out dry safety disclosures, leading consumers to overlook the drugs’ serious risks.   As a result, consumers may decide to use GLP-1 drugs without fully understanding the possible consequences. Incorrect information is "expensive." For individuals, it means wasted money, ignored health risks, and unrealistic expectations. For society, it means the wrong people chasing the drug, the right people struggling to access it, and a healthcare system left to deal with the mess (Akerlof, 1978).   When reliable information is difficult to process, consumers tend to rely on whatever signals are easiest to observe.   Market signalling and herd behaviour—why celebrity weight loss is so persuasive 🚨 Photo source: (Hutchinson, 2025) In the absence of full information, visible outcomes such as celebrity weight loss become especially persuasive (Spence, 1978). Celebrity body transformations act as a signal of product effectiveness. This signal appears credible because the costs of achieving these results differ across groups. Celebrities have better access to private healthcare, nutritionists, personal trainers, and other complementary resources, making weight loss more achievable. While ordinary consumers find it much harder to achieve similar outcomes. Studies show that 86% of U.S. adults have never consulted a registered dietitian (Eatright.org., 2025), and 33% cite cost as the main barrier (Patel, 2026), illustrating the difficulty for ordinary people to access professional nutrition support. This leads consumers to treat celebrity weight loss as evidence that GLP-1 drugs are highly effective, even though these outcomes often reflect factors beyond the drugs themselves. Because consumers cannot easily separate the drug’s effect from celebrities’ extra resources and lifestyle advantages, they overestimate its benefits. As a result, demand becomes distorted, contributing to inefficient market outcomes. These signals not only inform consumers but also shape behaviors. Suppose your friends, your classmates, or influencers you follow are all using the drug, you start to think it must be safe and effective. You don’t want to miss out, and you trust the people around you more than long, boring warnings. This is herd behavior-we follow the crowd because it feels easier and safer than deciding for ourselves (Hodkinson, 2019). Moral hazard-who bears the risk? ⚠️ The signalling effects further influence consumer behaviours, leading to moral hazard. Consumers who receive the drugs may start to think, “If this drug can help me lose weight anyway, maybe I do not need to worry so much about diet or exercise.” That kind of shift in behaviour is what economists call moral hazard. It is a circumstance where individuals take greater risks because they are protected from their potential losses (Pauly, 1968). If people begin turning to GLP-1 as a quick solution for losing weight, the demand for it will rocket high with increased prices, making the diabetic patients who need the medication for treatment being squeezed out, since they are unable to afford the GLP-1 drugs. This personal shortcut ends up with making access harder for the people who need the medicine most is a scenario called market misallocation. The key question is not only why consumers are persuaded, but also who bears the risk. In the GLP-1 market, private clinics gain from rising demand, especially when these drugs are promoted as quick and effective solutions. However, the costs of side effects are often borne by patients rather than by those driving the sales. This creates a classic moral hazard problem: when those who benefit do not fully bear the consequences, they may have weaker incentives to present balanced information or to limit promotion. The result is a market in which private rewards can exceed social benefits, pushing demand beyond what is efficient and making access harder for patients with greater medical needs. Final thoughts 🧠 The GLP-1 case displays how asymmetric information, misleading signalling and moral hazard lead to market misallocation. Celebrities and clinics make drugs look like an easy fix, pushing prices up and leaving diabetes patients no access to the drugs. So what can be done? (1)    Greater transparency: The FTC act requires celebrities disclose whether they are paid or have extra support like dietitians (Federal Trade Commission, 2022). (2)    Usage regulation: the BALANCE model restricts cosmetic use and set price caps that make the drug affordable for medical users, prioritising the use for patients with type 2 diabetes (KFF, 2026). Next time when you see the celebrities showing off their ‘easy’ weight loss, and all friends around you using the drug, just stay calm and think twice. But perhaps you will still chase the crowd! References      Alones Creative (2025) Blue Ozempic pens with yellow measuring tape on pink background [online image]. Getty Images/iStock. Available at: Getty Images website   Akerlof, G.A., 1978. The market for “lemons”: Quality uncertainty and the market mechanism. In Uncertainty in economics (pp. 235-251). Academic Press.   Eatright.org. (2025). A Seat at Every Table. [online] Available at: https://www.eatright.org/everytable.   Federal Trade Commission (2022). Health Products Compliance Guidance. [online] Federal Trade Commission. Available at: https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance.   Hodkinson, C., 2019. ‘Fear of Missing Out’(FOMO) marketing appeals: A conceptual model. Journal of Marketing Communications, 25(1), pp.65-88.   Hutchinson, E. (2025) 12 Celebs Who Totally Transformed After Taking Ozempic Or Other GLP-1’s, Women. Available at: https://www.women.com/1857718/celebs-totally-transformed-taking-ozempic-other-glp-1/. kffrainl (2025). Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford | KFF. [online] KFF. Available at: https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/.   KFF (2026). Medicare and Medicaid Gross Spending on GLP-1s Has Increased Substantially From 2019 to 2024, Though Net Spending Would Be Lower Taking Rebates Into Account. [online] KFF. Available at: https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/.   Muhammad, H.E. and Ahmed, A. (2025). From prescription to trend: the misuse of ozempic in the age of social media. Annals of Medicine and Surgery. [online] doi:https://doi.org/10.1097/ms9.0000000000003801.   Patel, V. (2026). US consumers turn to unaccredited nutrition advice from social media influencers and AI. [online] https://www.nutritioninsight.com. Available at: https://www.nutritioninsight.com/news/us-consumers-social-media-ai-nutrition-advice-survey.html.   Pauly, M.V., 1968. The economics of moral hazard: comment. The american economic review, 58(3), pp.531-537.   Spence, M., 1978. Job market signaling. In Uncertainty in economics (pp. 281-306). Academic Press.   Varghese, H.M. and Wingrove, P. (2026). Exclusive: Novo’s Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows. Reuters. [online] 28 Jan. Available at: https://www.reuters.com/business/media-telecom/novos-wegovy-ozempic-us-advertising-spend-doubles-rival-eli-lilly-data-shows-2026-01-28/.   Wegovy.com. (2026). Prescribing Information. [online] Available at: https://www.wegovy.com/prescribing-information.html.   zimmytws (2024) GLP-1 related drugs newspaper headlines with hand and magnifying glass [online image]. Shutterstock. Available at: Shutterstock   Labels: asymmetric information, market signalling, herd behaviour, moral hazard